Ultrasound-Driven Cavitation Reprograms Drug Response and Immune Sensitivity in Neuroendocrine Prostate Cancer

/in /by

Acoustic cavitation is emerging as a surprisingly powerful tool in the therapeutic landscape of neuroendocrine prostate cancer (NEPC), a disease state notoriously resistant to conventional treatments. By combining nanometer-scale lipid microbubbles with targeted ultrasound, researchers are leveraging a physical mechanism to overcome some of the most entrenched biological barriers in aggressive prostate cancer. At its […]

Read more

Confirmed Efficacy of Rucaparib in BRCA-Mutated mCRPC

/in , , /by

Rucaparib continues to strengthen its position in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that progresses despite hormonal therapy, with TRITON3 trial confirming not only its efficacy but also a predictable and manageable safety profile. In this phase 3 study of chemotherapy-naïve patients progressing after one prior androgen receptor pathway […]

Read more

Real-World OPTYX Study: Sustained Castration and Rapid Testosterone Recovery with Relugolix

/in /by

Relugolix (Orgovyx), the first oral androgen deprivation therapy approved for advanced prostate cancer, continues to show consistent performance in real-world settings. New data from the OPTYX study, a prospective observational analysis, provide further evidence on testosterone suppression, recovery, and PSA control in routine clinical practice. The study included 999 patients, predominantly with nonmetastatic disease and […]

Read more

Tipifarnib Shows Early Promise as an Adjuvant in Enzalutamide-Resistant Prostate Cancer

/in /by

Tipifarnib is an interesting repurposing candidate in advanced prostate cancer because it may interfere with a resistance mechanism that goes beyond androgen signaling alone. In a preclinical work presented during the AUA 2026 meeting, the drug reduced exosome release from aggressive castration-resistant prostate cancer cells, including 22Rv1 and CWR-R1, by about 30% at low dose, […]

Read more

ZNF281 Emerges as a Novel Driver and Therapeutic Target in Advanced Prostate Cancer

/in /by

ZNF281 is a Krüppel-type zinc-finger transcription factor previously implicated in cancer stemness, but its role in prostate cancer has remained largely unexplored. In a new study, researchers evaluated ZNF281 expression across human prostate cancer samples, including primary tumors, metastatic lymph nodes, and normal prostate tissue. The findings revealed significantly higher expression of ZNF281 in metastatic […]

Read more

NRG1-Driven Microenvironmental Resistance to PI3K Inhibition in Prostate Cancer

/in /by

Prostate cancer is driven not only by tumor genetics but also by dynamic interactions with the tumor microenvironment (TME). Although alterations in the PI3K pathway are common, especially in PTEN-deficient disease, clinical results with PI3K inhibitors, even when combined with androgen receptor (AR) blockade, have been underwhelming. New evidence suggests that resistance may be driven […]

Read more

Arginase 1 Suppression Makes Exercise Effective Against Prostate Cancer

/in /by

Exercise has consistently been linked to improved outcomes in prostate cancer, but the mechanisms behind this effect have remained unclear. A recent preclinical study provides a compelling explanation, identifying suppression of arginase 1 (Arg1) and modulation of arginine metabolism as key drivers of exercise-induced tumor control. Using a prostate-specific Pten-knockout mouse model, researchers observed that […]

Read more

IVMT-Rx-4: A New Experimental Drug That May Help Block Prostate Cancer Spread to Bone

/in /by

IVMT-Rx-4 is a preclinical stage experimental compound being studied for advanced prostate cancer, especially for cancer that spreads to bone. The basic idea is to interfere with a protein called MDA-9/Syntenin. This protein seems to help prostate cancer cells invade tissue, communicate with their environment, and settle in bone. By blocking that pathway, IVMT-Rx-4 may […]

Read more